Novartis AG (NOVN.SW)

CHF 88.04

(-0.77%)

Market Cap (In CHF)

172.24 Billion

Revenue (In CHF)

46.66 Billion

Net Income (In CHF)

14.85 Billion

Avg. Volume

2.79 Million

Currency
CHF
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
83.63-102.72
PE
-
EPS
-
Beta Value
0.505
ISIN
CH0012005267
CUSIP
H5820Q150
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dr. Vasant Narasimhan M.D.
Employee Count
-
Website
https://www.novartis.com
Ipo Date
1995-08-03
Details
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.